ReviewArchives of Razi Institute2025
Mechanisms of miRNAs (MicroRNAs) and Their Expression in Gastric Cancer.
Review in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epirubicin-Induced Upregulation of miR-143-3p and miR-145 Enhances Cytotoxicity in MCF-7, MDA-MB-231, and BT-474 Breast Cancer Cell Lines.Biochemical genetics · 2026Article
- Causal relationship between metabolic syndrome and gastric cancer: insights from comprehensive analysis and biomarker identification.Translational cancer research · 2026Article
- MiR-106b-5p promotes gastric cancer progression by directly targeting the tumor suppressor RBL2.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the fourth most prevalent form of cancer globally and the second leading cause of cancer-related fatalities worldwide. It was responsible for approximately 768,000 deaths. MicroRNAs (miRNAs), as short non-coding RNAs, undoubtedly play a central and decisive role in various types of cancer due to their interaction with target genes. Since the discovery of the identity and clinical functions of miRNAs in the past few decades, their potential as therapeutic targets in cancer research has been the focus of extensive study. The present study aims to investigate the role of microRNAs in gastric cancer, focusing on their expression, biogenesis, and potential as therapeutic biomarkers. MicroRNAs (miRNAs) have been identified as critical regulators of cell proliferation, signaling pathways, and the cell cycle. Furthermore, they have been identified as markers of metastasis in the stomach, liver, and lymph nodes, as well as indicators of response to chemotherapy in cancer patients. Numerous studies have demonstrated the efficacy of miRNAs in gastric cancer as biomarkers for cancer prognosis. A number of oncogenic clinical trials are currently underway, exploring the use of miRNAs in screening, diagnosis, and drug testing. However, many systematic molecular mechanisms, including a detailed investigation of miRNAs and their expression in gastric cancer, remain to be elucidated. Consequently, in addition to presenting the updated results of recent preclinical studies, researchers have investigated the biogenesis of miRNAs and their expression in cancer cells. It is hoped that the analysis of molecular interaction effects and the identification of target molecules and signaling pathways for miRNAs will contribute to the prevention and treatment of this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.